Investor Overview

Pardes is a clinical-stage biopharmaceutical company created by and for this moment to solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to develop novel drugs while reimagining the patient journey to access these medicines.

Stock
Quote

Webcasts

06/09/2022
at 11:30 AM EDT
03/09/2022
at 11:10 AM PST
02/15/2022
at 3:00 PM PST

Financial Information

Document Date Description Form View

Annual report which provides a comprehensive overview of the company for the past year

10-K View HTML EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.INS - XBRL INSTANCE FILE

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Amendment to a previously filed 10-Q

10-Q/A View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Initial filing by director officer or owner of more than ten percent.

3 View HTML

Initial filing by director officer or owner of more than ten percent.

3 View HTML

Initial filing by director officer or owner of more than ten percent.

3 View HTML

Contact
IR

Send us an investor-related question using the form below.